Hologic签署收购Reveal Genomics的正式协议-动脉网

Hologic Signs Definitive Agreement to Acquire Reveal Genomics

ANTARA News 等信源发布 2026-10-20 08:57



可切换为仅中文







Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer

此次收购将扩大豪洛捷公司的肿瘤诊断产品组合，从而为更多乳腺癌患者的治疗决策提供支持。

Marlborough, Mass.--(ANTARA/Business Wire)--Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. .

马萨诸塞州马尔伯勒——（ANTARA/美国商业资讯）——全球女性健康领域领导者豪洛捷公司（Hologic）今日宣布，已签署最终协议，收购位于西班牙巴塞罗那的精准肿瘤学公司Reveal Genomics。该公司致力于开发先进的基因组诊断测试，以助力癌症个性化治疗，包括其HER2DX检测，旨在帮助优化HER2阳性乳腺癌患者的治疗方案。

Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index

乳腺癌仍然是当今女性面临的最重大健康挑战之一。Reveal Genomics的检测产品与Hologic现有的肿瘤诊断产品（包括乳腺癌指数）高度互补。

(BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer.

(BCI) 检测，这是一种获指南认可的基因组检测方法，旨在为激素受体阳性（HR+）早期乳腺癌女性患者延长内分泌治疗的决策提供参考。

The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic’s diagnostic oncology solutions, with the combined offering of new and existing testing expected to help inform treatment decisions for more women with breast cancer.

豪洛捷现有的检测产品与Reveal Genomics的产品组合相结合，标志着豪洛捷在诊断肿瘤学解决方案方面的重大扩展。新旧检测产品的综合供应预计将为更多乳腺癌患者的治疗决策提供参考依据。

“Reveal Genomics’ portfolio is a strong strategic complement to our existing oncology offering within Diagnostic Solutions and would allow us to support even more women diagnosed with breast cancer,” said Vitor Rocha, CEO, Diagnostic Solutions at Hologic. “This acquisition demonstrates our commitment to innovation and meaningfully expands our ability to inform breast cancer treatment decisions, directly advancing our purpose to enable healthier lives everywhere, every day.”.

Hologic公司诊断解决方案首席执行官Vitor Rocha表示：“Reveal Genomics的产品组合是我们诊断解决方案业务现有肿瘤学产品的有力战略补充，将使我们能够为更多被诊断为乳腺癌的女性提供支持。此次收购彰显了我们对创新的承诺，并显著增强了我们为乳腺癌治疗决策提供信息支持的能力，直接推动我们实现‘每天、 everywhere 促进更健康生活’的使命。”

“We founded Reveal Genomics to bring precision oncology closer to patients and improve breast cancer treatment decisions,” said Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics. “Joining Hologic gives us the scale and capabilities to accelerate that mission and reach many more patients worldwide.”.

“我们创立Reveal Genomics，旨在让精准肿瘤学更贴近患者，并改善乳腺癌治疗决策，”Reveal Genomics首席执行官兼联合创始人Patricia Villagrasa-Gonzalez表示。“加入豪洛捷公司使我们具备规模和实力，以加速推进这一使命，惠及全球更多患者。”

Completion of the acquisition is subject to Spanish regulatory approval and other customary closing conditions.

本次收购的完成须以西班牙监管机构的批准及其他惯例交割条件为前提。

About Hologic, Inc.

关于豪洛捷公司

Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit

豪洛捷公司（Hologic, Inc.）是全球女性健康领域的领导者，致力于开发创新医疗技术，以有效检测、诊断和治疗健康状况，并提升全球护理标准。欲了解更多信息，请访问

www.hologic.com

and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.

并在 LinkedIn、Facebook、X、Instagram 和 YouTube 上关注我们。

About Reveal Genomics

关于 Reveal Genomics

REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data..

REVEAL GENOMICS, S.L. 是一家生物技术初创公司，致力于改变生物标志物在肿瘤学中的应用方式。公司专注于开发创新诊断工具，为癌症患者确定最佳治疗方案。该公司运用前沿技术、复杂的计算机应用程序以及机器学习，以揭示新的癌症研究数据。

Forward-Looking Statements

前瞻性陈述

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the proposed acquisition of the oncology services business of Reveal Genomics and the anticipated benefits, timing and effects of the transaction, as well as statements about the use of Hologic and Reveal Genomics products.

本新闻稿可能包含涉及风险和不确定性的前瞻性信息，包括关于拟议收购Reveal Genomics肿瘤服务业务的声明，以及对该交易的预期收益、时间安排和影响的声明，还有关于使用Hologic和Reveal Genomics产品的声明。

There can be no assurance the transaction will be completed on the anticipated terms or timing, or at all, including because required regulatory approvals or other customary closing conditions are not satisfied. There can also be no assurance that Hologic will successfully integrate Reveal Genomics’ business and personnel, that the acquired products will achieve the benefits described herein, that such benefits will be replicated in any particular manner with respect to an individual patient, or that these products will be commercially successful or achieve any expected level of sales, including as a result of coverage and reimbursement decisions by third-party payers.

无法保证交易将按预期的条款或时间表完成，甚至无法保证交易一定会完成，其中包括因未能获得所需的监管批准或未能满足其他惯例交割条件而导致交易无法完成的情况。此外，也无法保证豪洛捷公司能够成功整合Reveal Genomics的业务和人员，无法保证所收购的产品能够实现本文所述的益处，无法保证这些益处会以任何特定方式在个别患者身上重现，也无法保证这些产品会在商业上取得成功或达到任何预期的销售水平，包括因第三方付款方的承保和报销决定而影响销售的情况。

Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based..

Hologic 明确声明，其不承担任何义务或承诺公开发布对本文所述任何前瞻性陈述的更新或修订，以反映预期的任何变化，或反映此类陈述所依据的事件、条件或情况的任何变化。

Contacts

联系人

Media Contact

媒体联系人

Bridget Perry

布里奇特·佩里

Senior Director, Corporate Communications

企业传播高级总监

(+1) 508.263.8654

bridget.perry@hologic.com

Reporter: PR Wire